Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (7831)	5/13/2005 1:50:58 PM
From: Sergio H	Read Replies (1) \| Respond to of 23958

MDF also filled the hole nicely :-)

To: Galirayo who wrote (7831)	5/17/2005 9:56:38 AM
From: Galirayo	Respond to of 23958

[INGN] Press Release Source: Introgen Therapeutics, Inc. Introgen's Nanoparticle Cancer Therapy INGN 401 Demonstrates Promise in the Treatment of Lung Cancer Tuesday May 17, 8:00 am ET ORLANDO, Fla., May 17 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN - News) today provided an update of its ongoing clinical development of INGN 401, a nanoparticle formulation of the tumor suppressor gene FUS1. New preclinical data highlighting the potential of INGN 401 alone and in combination with Iressa® (Gefitinib) in the treatment of non-small cell lung cancer were reported. The data were presented today (Abstract #7081) at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando. Introgen researchers and their colleagues at The M. D. Anderson Cancer Center (MDACC) and The University of Texas Southwestern Medical Center are conducting the studies of INGN 401. [snip] biz.yahoo.com